SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
COPENHAGEN, Denmark, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Zealand today announces that the company's CEO Britt Meelby Jensen will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, 14 January 2016 at the Westin St. Francis Hotel in San Francisco, California. The presentation will take place at 10:30 am PT (7.30 pm CET).
The presentation will focus on the acceleration of Zealand's strategic direction towards value generation - from peptide to patient - and will outline the company's pipeline and news flow outlook for 2016.
An audio webcast of the presentation will be available on the Investor Relations section of the company's website at www.zealandpharma.com .
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: [email protected]
About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia(r) by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus(r)) which is on track for regulatory submission in the US in Q4 2015 and in the European Union in Q1 2016.
The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics.
The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
